Charles Edo De Bock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Charles Edo De Bock has a total of 580 co-authors. Here are the top co-authors by number of shared publications:
- Jan Cools
KU Leuven
43 shared publications Olga Gielen
22 shared publicationsJolien De Bie
19 shared publicationsKris Jacobs
19 shared publicationsNancy Boeckx
19 shared publicationsNicole Mentens
19 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Wiley in HemaSphere
- Vol. 10 (8)
The case for targeting enhancer regions in high‐risk TCF3::HLF‐positive B‐cell acute lymphoblastic leukemia
- 6 August 2026
- Published by Wiley in HemaSphere
- Vol. 10 (8)
Open AccessThe case for targeting enhancer regions in high‐risk TCF3::HLF‐positive B‐cell acute lymphoblastic leukemia
- Open Access
- 22 July 2026
- Published by Wiley in HemaSphere
- Vol. 10 (7) , e70438
Preclinical evaluation of the ROR1‐targeting antibody–drug conjugates zilovertamab vedotin and VLS‐211 against B‐cell ALL patient‐derived xenografts
Although survival rates for acute lymphoblastic leukemia (ALL) have improved dramatically over the past 60 years, outcomes vary across different molecular subtypes and risk categories, and a significant number of patients remain difficult to treat. ROR1 is a receptor tyrosine kinase expressed in B‐cell ALL, particularly in patients with TCF3 :: PBX1 gene rearrangements. ROR1 has served as the target of several immune‐based therapies including antibody–drug conjugates (ADCs), bispecific T‐cell engagers, and CAR T‐cell therapies. Here, we evaluated the ROR1‐targeting ADCs zilovertamab vedotin (ZV, previously known as MK‐2140 or VLS‐101) and VLS‐211 in vivo against a panel of ALL patient‐derived xenografts with variable ROR1 expression. Both agents showed modest activity, which was dependent on ROR1 expression. Notably, we identified pediatric patients with TCF3 :: HLF gene fusions, which is a highly chemoresistant ALL subtype, as having some of the highest ROR1 expression in pediatric ALL and show that this subtype is susceptible to targeting ROR1 via ADC‐based therapy. Given that ZV has a favorable toxicity profile in patients with hematological malignancies, it may have some utility in the treatment of very high‐risk pediatric B‐ALL, particularly cases with TCF3 :: HLF gene fusions.
- 22 July 2026
- Published by Wiley in HemaSphere
- Vol. 10 (7) , e70438
Open AccessPreclinical evaluation of the ROR1‐targeting antibody–drug conjugates zilovertamab vedotin and VLS‐211 against B‐cell ALL patient‐derived xenografts
Although survival rates for acute lymphoblastic leukemia (ALL) have improved dramatically over the past 60 years, outcomes vary across different molecular subtypes and risk categories, and a significant number of patients remain difficult to treat. ROR1 is a receptor tyrosine kinase expressed in B‐cell ALL, particularly in patients with TCF3 :: PBX1 gene rearrangements. ROR1 has served as the target of several immune‐based therapies including antibody–drug conjugates (ADCs), bispecific T‐cell engagers, and CAR T‐cell therapies. Here, we evaluated the ROR1‐targeting ADCs zilovertamab vedotin (ZV, previously known as MK‐2140 or VLS‐101) and VLS‐211 in vivo against a panel of ALL patient‐derived xenografts with variable ROR1 expression. Both agents showed modest activity, which was dependent on ROR1 expression. Notably, we identified pediatric patients with TCF3 :: HLF gene fusions, which is a highly chemoresistant ALL subtype, as having some of the highest ROR1 expression in pediatric ALL and show that this subtype is susceptible to targeting ROR1 via ADC‐based therapy. Given that ZV has a favorable toxicity profile in patients with hematological malignancies, it may have some utility in the treatment of very high‐risk pediatric B‐ALL, particularly cases with TCF3 :: HLF gene fusions.
- 16 July 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (3) , 268-269
OutFOXing a FENDRR bender in T-ALL.
- 16 July 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (3) , 268-269
OutFOXing a FENDRR bender in T-ALL.
- Open Access
- 19 November 2025
- Published by Wiley in HemaSphere
- Vol. 9 (11) , e70265
A new KAT on the block rewrites the epigenetic script in menin inhibitor‐resistant leukemia
- 19 November 2025
- Published by Wiley in HemaSphere
- Vol. 9 (11) , e70265
Open AccessA new KAT on the block rewrites the epigenetic script in menin inhibitor‐resistant leukemia
- 22 September 2025
- Published by Elsevier in Experimental Hematology
- Vol. 151, 105265
Building a transparent and functional laboratory culture: guidelines for creating a Laboratory Handbook for principal investigators
- 22 September 2025
- Published by Elsevier in Experimental Hematology
- Vol. 151, 105265
Building a transparent and functional laboratory culture: guidelines for creating a Laboratory Handbook for principal investigators
- Open Access
- 7 August 2025
- Published by Wiley in HemaSphere
- Vol. 9 (8) , e70193
Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia
- 7 August 2025
- Published by Wiley in HemaSphere
- Vol. 9 (8) , e70193
Open AccessCell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia
- Open Access
- 17 July 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2275-2280
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal
- 17 July 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2275-2280
Open AccessHypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal
- Open Access
- 16 April 2025
- Published by Wiley in HemaSphere
- Vol. 9 (4) , e70133
Patient‐derived xenografts: Practical considerations for preclinical drug testing
- 16 April 2025
- Published by Wiley in HemaSphere
- Vol. 9 (4) , e70133
Open AccessPatient‐derived xenografts: Practical considerations for preclinical drug testing
- Open Access
- 24 February 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (5) , 2201-2222
FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome
FAT1 cadherin exhibits dual tumor suppressor and oncogenic roles across various cancers, but its function in breast cancer remains unclear due to conflicting reports of mutational loss and overexpression. In this study, we demonstrate that FAT1 mRNA and protein levels are reduced during mammary transformation, an effect linked to promoter methylation rather than mutational events. Subtype-specific analysis reveals that high FAT1 expression correlates with poor outcomes in basal-like/triple-negative breast cancer (TNBC), while elevated FAT1 expression in luminal A/estrogen receptor-positive breast cancers is associated with improved patient prognosis. Functional studies in TNBC models using knockdown and overexpression approaches confirm that FAT1 promotes both cell proliferation and motility. High-throughput sequencing and biochemical assessments establish strong links between FAT1 phenotypes and the activation of PI3K-AKT signaling. Additionally, FAT1 manipulation induces significant changes in matrisome-related genes, extracellular matrix components, and integrin switching. Together, these findings define an oncogenic role for FAT1 in TNBC, providing mechanistic insights into how its regulation influences AKT signaling, cell proliferation, and motility.
- 24 February 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (5) , 2201-2222
Open AccessFAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome
FAT1 cadherin exhibits dual tumor suppressor and oncogenic roles across various cancers, but its function in breast cancer remains unclear due to conflicting reports of mutational loss and overexpression. In this study, we demonstrate that FAT1 mRNA and protein levels are reduced during mammary transformation, an effect linked to promoter methylation rather than mutational events. Subtype-specific analysis reveals that high FAT1 expression correlates with poor outcomes in basal-like/triple-negative breast cancer (TNBC), while elevated FAT1 expression in luminal A/estrogen receptor-positive breast cancers is associated with improved patient prognosis. Functional studies in TNBC models using knockdown and overexpression approaches confirm that FAT1 promotes both cell proliferation and motility. High-throughput sequencing and biochemical assessments establish strong links between FAT1 phenotypes and the activation of PI3K-AKT signaling. Additionally, FAT1 manipulation induces significant changes in matrisome-related genes, extracellular matrix components, and integrin switching. Together, these findings define an oncogenic role for FAT1 in TNBC, providing mechanistic insights into how its regulation influences AKT signaling, cell proliferation, and motility.
- Open Access
- 22 January 2025
- Published by Wiley in HemaSphere
- Vol. 9 (1) , e70084
Mastering fate: Redistributing a pioneer protein to rewrite leukemia's script
- 22 January 2025
- Published by Wiley in HemaSphere
- Vol. 9 (1) , e70084
Open AccessMastering fate: Redistributing a pioneer protein to rewrite leukemia's script